This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • One Year Study of Rifaximin Delayed Release (DR) i...
Clinical trial

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Read time: 1 mins
Last updated:11th Sep 2014

The primary objective is to determine the efficacy of rifaximin DR tablets vs. placebo for the induction of clinical remission and endoscopic response following 16 weeks of treatment in subjects presenting with active moderate Crohn's disease. A key secondary objective is to evaluate clinical and endoscopic remission following an additional 36 weeks of treatment.

Category Value
Study start date 2014-09-11

View full details